

EP335/#563

NEUTROPHIL-TO-LYMPHOCYTE RATIO AND PLATELETS-LYMPHOCYTES RATIO AS RESPONSE MARKERS IN OVARIAN CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY

Aref Zribi*, Ikram Burney. *The Sultan Qaboos Comprehensive Cancer Care and Research, Medical Oncology, muscat, Oman*

10.1136/ijgc-2023-IGCS.394

Introduction Systemic inflammatory responses are closely associated with cancer initiation, progression and metastasis, consequently, inflammatory markers, including the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have been studied in many cancers. The objective of this study was to evaluate the impact of the NLR and PLR as a response indicator to the neoadjuvant chemotherapy (NACT) in high grade serous localized ovarian cancer (HGSOC)

Methods A total of 30 patients who had received NACT followed by interval debulking surgery were eligible for retrospective analysis. The pretreatment and post-treatment PLR, NLR in all patients were calculated based on complete blood counts

Results The median age of our patient was 50 ± 9 years, 10% were stage II and 90% were stage III the pretreatment NLR and PLR were correlated with response to NACT, Patients with lower $NLR < 2.5$ and $PLR < 185$ had a significantly better response rate to NACT versus those with a higher NLR and PLR. the decrease in NLR and PLR rates after chemotherapy can be considered as an early prediction of response to treatment. PLR and NLR are high in the presence of residual tumor after surgery. $PLR > 200$ and $NLR > 2.6$ were biomarkers of suboptimal surgery. PLR and NLR levels are well correlated with serum CA125 levels.

Conclusion/Implications Our results suggested that NLR and PLR were well-connected with response to NACT in patients with HGSOC. As a response indicator, NLR and PLR may predict benefit from chemotherapy. Relationship between NLR, PLR and CA125 may provide new information about the pathogenesis of ovarian cancer.

AS12. Palliative care

EP336/#874

SEMIQUANTITATIVE LYMPHOSCINTIGRAPHY IN GYNECOLOGIC CANCER PATIENTS WITH LOWER EXTREMITY LYMPHEDEMA: PREDICTION OF SHORT-TERM OUTCOME AFTER LYMPHATICOVENOUS ANASTOMOSIS

¹Min Jong Song, ²Jung Hwan Ahn*, ³Eun Ji Han. ¹Yeouido St. Mary's Hospital, *Obstetrics and Gynecology, Seoul, Korea, Republic of*; ²Yonsei University Wonju College of Medicine, *Republic of Korea, (South), Obstetrics and Gynecology, Wonju, Korea, Republic of*; ³Yeouido St. Mary's Hospital, *College of Medicine, The Catholic University of Korea, Nuclear Medicine, Seoul, Korea, Republic of*

10.1136/ijgc-2023-IGCS.395

Introduction We aimed to evaluate the predictive value of semiquantitative lymphoscintigraphy in patients who underwent lymphovenous anastomosis (LVA) for lower extremity lymphedema (LEL).

Methods We retrospectively reviewed patients with LEL who underwent preoperative lymphoscintigraphy and LVA. From

the lymphoscintigraphy, the transport index in 120 min (TI₁₂₀) and 240 min (TI₂₄₀) were respectively calculated by visual assessment of 5 criteria: lymphatic transport kinetics, distribution pattern, time to appearance of lymph nodes, visualization of lymph nodes, and visualization of vessels. The volume differential (VD) between the affected and the contralateral unaffected lower extremities (LEs) was calculated and the volume differential reduction at 1 (VDR₁), 3 (VDR₃), and 6 months (VDR₆) were respectively calculated to evaluate the postoperative outcome.

Results In total, 46 patients were included. According to Campisi's stage, the majority of patients (76%) had stage III disease. In the lymphoscintigraphy, the mean TI₁₂₀ and TI₂₄₀ of 46 affected LEs were 26.8 ± 11.4 and 25.9 ± 11.3 , respectively. The mean preoperative VD was $26 \pm 14\%$ (range, 2–59). Campisi's stage increased with BMI, TI, and preoperative VD. There were significant positive correlations of TI with BMI and preoperative VD, respectively ($p < 0.05$). In postoperative assessment, the mean VDR₁, VDR₃, and VDR₆ were $60 \pm 99\%$ (range, -9–526), $78 \pm 121\%$ (range, 5–572), and $74 \pm 116\%$ (range, -92–499), respectively. There was significant negative correlation between preoperative VD and each VDR ($p < 0.05$). Both TI₁₂₀ and TI₂₄₀ showed significant negative correlation with VDR₃ and VDR₆ ($p < 0.05$), although not VDR₁.

Conclusion/Implications This study suggests that semiquantitative lymphoscintigraphy using TI can be valuable as an effective tool for assessment of preoperative severity.

EP338/#147

A PROSPECTIVE COHORT STUDY OF NINJIN-YO'EITOU FOR FATIGUE, MALAISE, ANOREXIA AND ANEMIA IN OLAPARIB TREATMENT FOR THE PATIENTS WITH OVARIAN CANCER; KCOG-G1904 STUDY

¹Satoe Fujiwara*, ¹Ruri Nishie, ²Fuminori Ito, ²Makiko Taniguchi, ³Masato Aoki, ³Hidekatsu Nakai, ⁴Kazuto Tasaki, ⁵Emi Yoshioka, ⁵Kensuke Hori, ⁶Atsushi Arakawa, ⁷Taiger Koike, ⁷Yoshimasa Bomoto, ⁸Takashi Motohashi, ⁵Kimihiko Ito. ¹Osaka Medical and Pharmaceutical University, *Department of Obstetrics and Gynecology, Takatsuki, Japan*; ²Nara Prefecture General Medical Center, *Department of Obstetrics and Gynecology, Nara, Japan*; ³Kindai University, *Department of Obstetrics and Gynecology, Osakasayama, Japan*; ⁴Kurume University, *Department of Obstetrics and Gynecology, Kurume, Japan*; ⁵Kansai Rosai Hospital, *Department of Obstetrics and Gynecology, Amagasaki, Japan*; ⁶Nagoya City University West Medical Center, *Department of Obstetrics and Gynecology, Nagoya, Japan*; ⁷Gifu University, *Department of Obstetrics and Gynecology, Gifu, Japan*; ⁸Tokyo Women's Medical University, *Department of Obstetrics and Gynecology, Tokyo, Japan*

10.1136/ijgc-2023-IGCS.396

Introduction Olaparib is an oral poly (ADP-ribose) polymerase inhibitor that has shown antitumor activity in patients with advance or recurrent ovarian cancer. It is associated with adverse side effects, including fatigue, malaise, anorexia and anemia, which may force its discontinuation. Ninjin'yoeitou (NYT) is a herbal medicine that can effectively treat these adverse events. However, the efficacy of NYT in reducing these side effects with Olaparib is not clear.

Methods The present study included 45 patients who received Olaparib for newly diagnosed advanced or platinum sensitive recurrent ovarian cancer at eight Kansai Clinical Oncology Group (KCOG)-related institutions. Treatment-related adverse events were graded with use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Quality of life was assessed with the Functional

Assessment of Cancer Therapy-Ovarian Cancer (FACT-O) questionnaire (completed at baseline and every month until 6 months had passed or disease progression), the FACT/NCCN Ovarian Symptom Index (FOSI), and the Trial Outcome Index (TOI).

Results Grade 3 or higher anemia occurred in 13 of 45 patients (29%), Grade 2 or higher fatigue in 6 (13%), and anorexia in 2 (4%). The incidence of discontinuation due to side effects was 15% (7/45). Moreover, NYT could maintain quality of life under all measures: FACT-O, TOI, and FOCL. NYT also significantly improved fatigue after the start of Olaparib administration ($p=0.017$).

Conclusion/Implications NYT could maintain quality of life by suppressing Olaparib-induced fatigue and help the long-term maintenance therapy of Olaparib in patients with ovarian cancer by reducing these adverse events.

AS13. Patient advocacy

EP339/#372

LYMPHEDEMA IN GYNECOLOGICAL CANCER SURVIVOR; A NATIONWIDE COHORT STUDY

Su Jeong Lee*, Chan Joo Kim, Jin Hwi Kim. *Catholic University of Korea Uijeongbu St Mary's Hospital, Gynecologic Oncology, Uijeongbu City, Gyeonggi-do, Korea, Republic of*

10.1136/ijgc-2023-IGCS.397

Introduction Leg lymphedema after gynecological cancer treatment is common and negatively affects the quality of life and function of patients. This study investigated the cumulative incidence and risk factors of lymphedema in gynecological cancer patients, as well as utilization of health care resources for post-treatment lymphedema.

Methods Using the Korean National Health Insurance Service (NHIS) database, we conducted a nationwide, retrospective cohort study of patients with gynecological cancer treatment. We analyze the incidence and risk factors of lymphedema by using cox proportional hazards regression models. We also analyzed diagnostic and treatment claim codes to find out trend or costs of utilization of health care resources for lymphedema treatment.

Results A total of 93,218 patients with gynecological cancer were evaluated between January 2004 and December 2017. Among them, total 10,451(11.2%) developed lymphedema. Incidences of lymphedema were 11.4%, 13.1%, and 9.16% in cervical cancer, endometrial cancer and ovarian cancer respectively. Age and multimodal treatment are considered to be possible risk factors for lymphedema in patients with gynecological cancer ($p < 0.001$), while residence and income quartile were not associated with lymphedema in gynecologic cancer patients. The expands of health care resources for the treatment of lymphedema has increased over the years.

Conclusion/Implications Lymphedema is a common complication affecting women with gynecological cancer. This is the first population-based the first population-based study to identify risk factors for lymphedema in gynecological cancer patients. National healthcare costs for lymphedema treatment are increasing in Korean society. Health care providers should give attentions for high-risk lymphedema group during and after cancer-related treatment.

EP340/#681

CONTRACEPTION COUNSELLING AND PREGNANCY SCREENING PRACTICE WITHIN AN ONCOLOGIC DEPARTMENT; AN INSTITUTION EXPERIENCE

Jade Desilets, Marie-Catherine Viau, Megan Schneiderman, Luisa Luciani Castiglio, Selda Elmas, Shuk On Annie Leung. *Cancer Research Program RI-MUHC, Gynecologic Oncology, Montreal, Canada*

10.1136/ijgc-2023-IGCS.398

Introduction The goal of this study is to describe the pregnancy screening and contraception counselling practice within the Departments of Oncology at McGill University Health Center as part of a needs assessment to develop a referral pathway to a complex contraception clinic.

Methods An electronic survey comprising 21 questions was delivered via email to 187 clinicians of the oncology departments providing care to patients with cancer. The survey assessed counselling practice and level of comfort regarding contraception while patients are undergoing oncologic treatment. Descriptive statistics were used for analysis.

Results Of the 187 members of the oncologic department, 70 responded to the survey including oncologist, nurses, pharmacist and radiation technologists. Forty-seven percent (47%, $n=33$) reported always advising female patients to avoid pregnancy while on active treatment and only 36% ($n=22$) felt comfortable providing contraception counselling. The most common reasons identified by respondents for lack of comfort with contraception counseling was lack required knowledge (36%, $n=25$). Amongst oncologists ($n=22$), 68% ($n=15$) reported rarely ordering a pregnancy test prior to initiation of cancer treatment. All respondents would refer their patients to complex contraception clinic pre-treatment should it be available. Based on these results a referral pathway to a complex contraception clinic was developed.

Conclusion/Implications This survey shows a low rate of pre-treatment pregnancy screening and contraception counselling through the oncology department with lack of knowledge identified as the main barrier. This highlights an opportunity for improvement with the introduction of systematic pregnancy testing and contraception counselling via the implementation of a referral pathway to contraception specialist.

EP341/#890

THE NEED OF A BETTER DISCUSSION BETWEEN DOCTORS AND PATIENTS WITH REGARDS OF FERTILITY PRESERVATION AFTER ANTI CERVICAL CANCER TREATMENTS

Bar Levy*. *HBait Shel Bar – Israel Women's Cancer Association (RA), Management, Tel Aviv, Israel*

10.1136/ijgc-2023-IGCS.399

Introduction According to studies, the age range of cervical cancer patients usually ranges between the age 35 to 39 or 60 to 64 years old and is relatively younger than other gynecological cancers' age range. In this young age range, a patient might want to give birth after treatments.

Methods A call for answers to a survey was published in the Israeli Cervical Cancer Facebook Community, and community